http://streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 15 Jun 2026 17:57:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Quince+Therapeutics%2C++++++For%3A+Jun+11++Filed+by%3A+Lamond+David/26648848.html si-local-file:///var/storage/secattach/20260615/26648848.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Quince+Therapeutics%2C++++++For%3A+Jun+11++Filed+by%3A+Lamond+David/26648848.html Mon, 15 Jun 2026 17:57:00 -0400 O.37557959 QNCX http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Quince+Therapeutics%2C++++++For%3A+Jun+11++Filed+by%3A+Lamond+David/26648848.html si-local-file:///var/storage/secattach/20260615/26648848.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Quince+Therapeutics%2C++++++For%3A+Jun+11++Filed+by%3A+Lamond+David/26648848.html Mon, 15 Jun 2026 17:57:00 -0400 O.37557959 QNCX http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Quince+Therapeutics%2C++++++For%3A+Jun+11++Filed+by%3A+Senner+Christopher+J./26648827.html si-local-file:///var/storage/secattach/20260615/26648827.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Quince+Therapeutics%2C++++++For%3A+Jun+11++Filed+by%3A+Senner+Christopher+J./26648827.html Mon, 15 Jun 2026 17:52:00 -0400 O.37557959 QNCX http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Quince+Therapeutics%2C++++++For%3A+Jun+11++Filed+by%3A+Senner+Christopher+J./26648827.html si-local-file:///var/storage/secattach/20260615/26648827.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Quince+Therapeutics%2C++++++For%3A+Jun+11++Filed+by%3A+Senner+Christopher+J./26648827.html Mon, 15 Jun 2026 17:52:00 -0400 O.37557959 QNCX http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Quince+Therapeutics%2C++++++For%3A+May+18++Filed+by%3A+Roberts+Brigette/26636925.html si-local-file:///var/storage/secattach/20260611/26636925.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Quince+Therapeutics%2C++++++For%3A+May+18++Filed+by%3A+Roberts+Brigette/26636925.html Thu, 11 Jun 2026 17:30:00 -0400 O.37557959 QNCX http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Quince+Therapeutics%2C++++++For%3A+May+18++Filed+by%3A+Roberts+Brigette/26636925.html si-local-file:///var/storage/secattach/20260611/26636925.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Quince+Therapeutics%2C++++++For%3A+May+18++Filed+by%3A+Roberts+Brigette/26636925.html Thu, 11 Jun 2026 17:30:00 -0400 O.37557959 QNCX http://www.streetinsider.com/SEC+Filings/Form++3++++++++++Quince+Therapeutics%2C++++++For%3A+May+18++Filed+by%3A+Roberts+Brigette/26636909.html si-local-file:///var/storage/secattach/20260611/26636909.html http://www.streetinsider.com/SEC+Filings/Form++3++++++++++Quince+Therapeutics%2C++++++For%3A+May+18++Filed+by%3A+Roberts+Brigette/26636909.html Thu, 11 Jun 2026 17:28:00 -0400 O.37557959 QNCX http://www.streetinsider.com/SEC+Filings/Form++3++++++++++Quince+Therapeutics%2C++++++For%3A+May+18++Filed+by%3A+Roberts+Brigette/26636909.html si-local-file:///var/storage/secattach/20260611/26636909.html http://www.streetinsider.com/SEC+Filings/Form++3++++++++++Quince+Therapeutics%2C++++++For%3A+May+18++Filed+by%3A+Roberts+Brigette/26636909.html Thu, 11 Jun 2026 17:28:00 -0400 O.37557959 QNCX http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Quince+Therapeutics%2C++++++For%3A+Jun+11/26636702.html si-local-file:///var/storage/secattach/20260611/26636702.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Quince+Therapeutics%2C++++++For%3A+Jun+11/26636702.html Thu, 11 Jun 2026 17:07:00 -0400 O.37557959 QNCX http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Quince+Therapeutics%2C++++++For%3A+Jun+11/26636702.html si-local-file:///var/storage/secattach/20260611/26636702.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Quince+Therapeutics%2C++++++For%3A+Jun+11/26636702.html Thu, 11 Jun 2026 17:07:00 -0400 O.37557959 QNCX http://www.streetinsider.com/SEC+Filings/Form++D++++++++++Quince+Therapeutics%2C+++++++++++++++++/26634501.html si-local-file:///var/storage/secattach/20260611/26634501.html http://www.streetinsider.com/SEC+Filings/Form++D++++++++++Quince+Therapeutics%2C+++++++++++++++++/26634501.html Thu, 11 Jun 2026 12:02:00 -0400 O.37557959 QNCX http://www.streetinsider.com/SEC+Filings/Form++D++++++++++Quince+Therapeutics%2C+++++++++++++++++/26634501.html si-local-file:///var/storage/secattach/20260611/26634501.html http://www.streetinsider.com/SEC+Filings/Form++D++++++++++Quince+Therapeutics%2C+++++++++++++++++/26634501.html Thu, 11 Jun 2026 12:02:00 -0400 O.37557959 QNCX http://www.streetinsider.com/SEC+Filings/Form++D++++++++++Quince+Therapeutics%2C+++++++++++++++++/26634498.html si-local-file:///var/storage/secattach/20260611/26634498.html http://www.streetinsider.com/SEC+Filings/Form++D++++++++++Quince+Therapeutics%2C+++++++++++++++++/26634498.html Thu, 11 Jun 2026 12:01:00 -0400 O.37557959 QNCX http://www.streetinsider.com/SEC+Filings/Form++D++++++++++Quince+Therapeutics%2C+++++++++++++++++/26634498.html si-local-file:///var/storage/secattach/20260611/26634498.html http://www.streetinsider.com/SEC+Filings/Form++D++++++++++Quince+Therapeutics%2C+++++++++++++++++/26634498.html Thu, 11 Jun 2026 12:01:00 -0400 O.37557959 QNCX http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Quince+Therapeutics%2C+++++++++++++++++++Filed+by%3A+INTEGRATED+CORE+STRATEGIES+%28US%29+LLC/26630488.html si-local-file:///var/storage/secattach/20260610/26630488.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Quince+Therapeutics%2C+++++++++++++++++++Filed+by%3A+INTEGRATED+CORE+STRATEGIES+%28US%29+LLC/26630488.html Wed, 10 Jun 2026 16:39:00 -0400 O.37557959 QNCX http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Quince+Therapeutics%2C+++++++++++++++++++Filed+by%3A+INTEGRATED+CORE+STRATEGIES+%28US%29+LLC/26630488.html si-local-file:///var/storage/secattach/20260610/26630488.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Quince+Therapeutics%2C+++++++++++++++++++Filed+by%3A+INTEGRATED+CORE+STRATEGIES+%28US%29+LLC/26630488.html Wed, 10 Jun 2026 16:39:00 -0400 O.37557959 QNCX http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Quince+Therapeutics%2C++++++For%3A+May+20/26536727.html si-local-file:///var/storage/secattach/20260521/26536727.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Quince+Therapeutics%2C++++++For%3A+May+20/26536727.html Thu, 21 May 2026 17:07:00 -0400 O.37557959 QNCX http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Quince+Therapeutics%2C++++++For%3A+May+20/26536727.html si-local-file:///var/storage/secattach/20260521/26536727.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Quince+Therapeutics%2C++++++For%3A+May+20/26536727.html Thu, 21 May 2026 17:07:00 -0400 O.37557959 QNCX http://www.streetinsider.com/SEC+Filings/Form++8-KA++++++Quince+Therapeutics%2C++++++For%3A+May+17/26514175.html si-local-file:///var/storage/secattach/20260518/26514175.html http://www.streetinsider.com/SEC+Filings/Form++8-KA++++++Quince+Therapeutics%2C++++++For%3A+May+17/26514175.html Mon, 18 May 2026 16:20:00 -0400 O.37557959 QNCX http://www.streetinsider.com/SEC+Filings/Form++8-KA++++++Quince+Therapeutics%2C++++++For%3A+May+17/26514175.html si-local-file:///var/storage/secattach/20260518/26514175.html http://www.streetinsider.com/SEC+Filings/Form++8-KA++++++Quince+Therapeutics%2C++++++For%3A+May+17/26514175.html Mon, 18 May 2026 16:20:00 -0400 O.37557959 QNCX http://www.streetinsider.com/FDA/Quince+Therapeutics+reports+phase+2a+trial+results+for+LAM-001+in+lung+disease/26511786.html <p>Quince Therapeutics Inc. (NASDAQ: QNCX) reported data from a phase 2a study of LAM-001, an inhaled formulation of rapamycin, showing improvements in patients with pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.</p> <p>The 24-week, open-label trial enrolled 10 patients across four clinical sites. Six patients completed the study, including four with PH-ILD who were receiving stable doses of treprostinil therapy. The company acquired LAM-001 through its acquisition of Orphai Therapeutics.</p> <p>In the PH-ILD subgroup of four patients, six-minute walk distance improved by 67.4 meters and pulmonary vascular resistance decreased by 33.9% in supine position at 24 weeks. The broader http://www.streetinsider.com/FDA/Quince+Therapeutics+reports+phase+2a+trial+results+for+LAM-001+in+lung+disease/26511786.html Mon, 18 May 2026 10:22:03 -0400 A.35954321 A.50216777 A.60012014 O.00638181 O.20737027 O.37557959 O.54516537 QNCX http://www.streetinsider.com/FDA/Quince+Therapeutics+reports+phase+2a+trial+results+for+LAM-001+in+lung+disease/26511786.html <p>Quince Therapeutics Inc. (NASDAQ: QNCX) reported data from a phase 2a study of LAM-001, an inhaled formulation of rapamycin, showing improvements in patients with pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.</p> <p>The 24-week, open-label trial enrolled 10 patients across four clinical sites. Six patients completed the study, including four with PH-ILD who were receiving stable doses of treprostinil therapy. The company acquired LAM-001 through its acquisition of Orphai Therapeutics.</p> <p>In the PH-ILD subgroup of four patients, six-minute walk distance improved by 67.4 meters and pulmonary vascular resistance decreased by 33.9% in supine position at 24 weeks. The broader http://www.streetinsider.com/FDA/Quince+Therapeutics+reports+phase+2a+trial+results+for+LAM-001+in+lung+disease/26511786.html Mon, 18 May 2026 10:22:03 -0400 A.35954321 A.50216777 A.60012014 O.00638181 O.20737027 O.37557959 O.54516537 QNCX http://www.streetinsider.com/FDA/Quince+Therapeutics+reports+phase+2a+trial+results+for+LAM-001+in+lung+disease/26511786.html <p>Quince Therapeutics Inc. (NASDAQ: QNCX) reported data from a phase 2a study of LAM-001, an inhaled formulation of rapamycin, showing improvements in patients with pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.</p> <p>The 24-week, open-label trial enrolled 10 patients across four clinical sites. Six patients completed the study, including four with PH-ILD who were receiving stable doses of treprostinil therapy. The company acquired LAM-001 through its acquisition of Orphai Therapeutics.</p> <p>In the PH-ILD subgroup of four patients, six-minute walk distance improved by 67.4 meters and pulmonary vascular resistance decreased by 33.9% in supine position at 24 weeks. The broader http://www.streetinsider.com/FDA/Quince+Therapeutics+reports+phase+2a+trial+results+for+LAM-001+in+lung+disease/26511786.html Mon, 18 May 2026 10:22:03 -0400 A.35954321 A.50216777 A.60012014 O.00638181 O.20737027 O.37557959 O.54516537 QNCX http://www.streetinsider.com/FDA/Quince+Therapeutics+reports+phase+2a+trial+results+for+LAM-001+in+lung+disease/26511786.html <p>Quince Therapeutics Inc. (NASDAQ: QNCX) reported data from a phase 2a study of LAM-001, an inhaled formulation of rapamycin, showing improvements in patients with pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.</p> <p>The 24-week, open-label trial enrolled 10 patients across four clinical sites. Six patients completed the study, including four with PH-ILD who were receiving stable doses of treprostinil therapy. The company acquired LAM-001 through its acquisition of Orphai Therapeutics.</p> <p>In the PH-ILD subgroup of four patients, six-minute walk distance improved by 67.4 meters and pulmonary vascular resistance decreased by 33.9% in supine position at 24 weeks. The broader http://www.streetinsider.com/FDA/Quince+Therapeutics+reports+phase+2a+trial+results+for+LAM-001+in+lung+disease/26511786.html Mon, 18 May 2026 10:22:03 -0400 A.35954321 A.50216777 A.60012014 O.00638181 O.20737027 O.37557959 O.54516537 QNCX http://www.streetinsider.com/FDA/Quince+Therapeutics+reports+phase+2a+trial+results+for+LAM-001+in+lung+disease/26511786.html <p>Quince Therapeutics Inc. (NASDAQ: QNCX) reported data from a phase 2a study of LAM-001, an inhaled formulation of rapamycin, showing improvements in patients with pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.</p> <p>The 24-week, open-label trial enrolled 10 patients across four clinical sites. Six patients completed the study, including four with PH-ILD who were receiving stable doses of treprostinil therapy. The company acquired LAM-001 through its acquisition of Orphai Therapeutics.</p> <p>In the PH-ILD subgroup of four patients, six-minute walk distance improved by 67.4 meters and pulmonary vascular resistance decreased by 33.9% in supine position at 24 weeks. The broader http://www.streetinsider.com/FDA/Quince+Therapeutics+reports+phase+2a+trial+results+for+LAM-001+in+lung+disease/26511786.html Mon, 18 May 2026 10:22:03 -0400 A.35954321 A.50216777 A.60012014 O.00638181 O.20737027 O.37557959 O.54516537 QNCX